Effects of sulforaphane on negative symptoms and cognitive impairments in chronic schizophrenia patients: A randomized double-blind trial
Chen H, Lu J, Zou T, Teng Z, Qin Y, Wu R, Yan Y, Fu K, Jiang W, Ju Y, Zhu R, Mo J, Lu J, Huang J
Journal of psychiatric research · 5 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Universidad u hospital
- Central South University
- Gobierno
- Natural Science Foundation of Hunan Province
- Gobierno
- Science and Technology Program of Hunan Province
- Gobierno
- Hunan Provincial Natural Science Foundation
- Subvenciones
- National Natural Science Foundation of China (82072096); Natural Science Foundation of Hunan Province (2022JJ40691); Science and Technology Program of Hunan Province (2024RC3055)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2025-03-13 · J Psychiatr Res · vol. 184 · págs. 464–472
- Editorial
- Elsevier BV
- Citado
- 9 citas · más que el 96% de estudios similares · 5.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 58 trabajos
- Acceso
- De pago
- Áreas de investigación
- Schizophrenia research and treatment · Tryptophan and brain disorders · Parkinson's Disease Mechanisms and Treatments
- Palabras clave
- sulforaphane, chronic schizophrenia, negative symptoms, cognitive impairment, oxidative stress, neuroinflammation, antioxidants, anti-inflammatory agents, adjunctive therapy, PANSS, MATRICS Consensus Cognitive Battery
- MeSH
- humans, chronic disease, isothiocyanates, sulfoxides, antipsychotic agents, double-blind method, schizophrenia, adult, middle aged, female, male, cognitive dysfunction, outcome assessment, health care
16 autores
- Haiyu Chen🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Jinjun Lu · autor de correspondencia
- Jinjun Lu🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Tianxiang Zou🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Ziwei Teng🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Yue Qin🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Renrong Wu🇨🇳Central South University; Second Xiangya Hospital of Central South University
- Yeliang Yan
- Kai Fu
- Wenjuan Jiang
- Yunxia Ju🇨🇳Third Hospital of Changsha
- Riyong Zhu🇨🇳Third Hospital of Changsha
- Jianzhong Mo🇨🇳Third Hospital of Changsha
- Jian Lü🇨🇳 · autor de correspondenciaCentral South University; Second Xiangya Hospital of Central South University
- Jian Lü
- Jing Hua Huang🇨🇳 · autor de correspondenciaCentral South University; Second Xiangya Hospital of Central South University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The pathological mechanisms of negative symptoms and cognitive impairment in schizophrenia may involve oxidative stress and neuroinflammation. Sulforaphane is an organosulfur compound with antioxidant and anti-inflammatory properties. This study aimed to evaluate its efficacy in ameliorating negative symptoms and cognitive impairments in chronic schizophrenia patients.
Method
This 24-week double-blind randomised trial (NCT04521868) recruited schizophrenia patients with significant negative symptoms. Participants were randomly assigned to receive either sulforaphane or placebo and were required to complete at least one post-intervention assessment to evaluate changes in negative symptoms and cognitive functioning. Existing antipsychotic medication treatment regimens remained unchanged throughout the study.
Results
A total of 42 patients were included in the statistical analysis, with 28 receiving sulforaphane and 14 assigned to placebo. Sulforaphane significantly reduced the Negative Symptom Score from the PANSS 5-Factor model between groups (p = 0.007) and exhibited a significant time-by-group interaction (p = 0.023), with more pronounced group differences observed after 12 weeks compared to 24 weeks of treatment. Sulforaphane also demonstrated a significant reduction in the original PANSS Negative Symptom Score between groups (p = 0.029). However, sulforaphane showed no significant effects on the MATRICS Consensus Cognitive Battery composite score or its subscores.
Conclusion
The significant improvements in the Negative Symptom Score from the PANSS 5-Factor model and the original PANSS Negative Symptom Score in the sulforaphane group suggest the potential of sulforaphane as an adjunctive treatment for ameliorating negative symptoms in chronic schizophrenia. Further research is warranted to explore the effects of sulforaphane on cognitive function.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.